Inhibrx Biosciences Files 8-K Report

TL;DR

Inhibrx Biosciences filed an 8-K on Jan 21, 2025, covering disclosures and other events.

AI Summary

On January 21, 2025, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. The company, previously known as Ibex SpinCo, Inc., changed its name on January 11, 2024, and is incorporated in Delaware.

Why It Matters

This 8-K filing provides updates on Inhibrx Biosciences' corporate events and financial disclosures, which are important for investors to monitor the company's status and compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Inhibrx Biosciences, Inc. (company) — Registrant
• Ibex SpinCo, Inc. (company) — Former company name
• January 21, 2025 (date) — Date of report
• January 11, 2024 (date) — Date of name change
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share INBX The Nasdaq Global Market

Filing Documents

• inhibrx-20250121.htm (8-K) — 32KB
• exhibit991-pressreleasecol.htm (EX-99.1) — 14KB
• inhibrxlogo-largea.jpg (GRAPHIC) — 939KB
• 0002007919-25-000007.txt ( ) — 1475KB
• inhibrx-20250121.xsd (EX-101.SCH) — 2KB
• inhibrx-20250121_lab.xml (EX-101.LAB) — 23KB
• inhibrx-20250121_pre.xml (EX-101.PRE) — 13KB
• inhibrx-20250121_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 21, 2025, Inhibrx Biosciences, Inc. ("Inhibrx") issued a press release announcing preliminary data regarding ozekibart as discussed in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On January 21, 2025, Inhibrx announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). Efficacy was assessed in 10 of the 13 patients who received at least one dose of ozekibart, based on RECIST v1.1 criteria. Results demonstrated one complete response (CR), three partial responses (PR), and six cases of stable disease (SD). Durable disease control lasting 180 days was observed in 46.2% of patients, with a median progression-free survival (PFS) of 7.85 months. All patients had received at least one prior line of systemic therapy (median: two; range: 1–6). The patient achieving a CR had undergone three prior lines of therapy, and two PRs occurred in patients who had failed prior FOLFIRI-based treatments. Ozekibart-related treatment-emergent adverse events (TEAEs) were reported in 84.6% of patients, with most being grade 1 or 2 in severity. Grade 3 TEAEs were observed in 30.8% of patients. The most common ozekibart-related TEAEs included nausea, increased alanine aminotransferase, diarrhea, and fatigue, with the majority being low-grade. Inhibrx has initiated a new expansion cohort to validate these findings in a more uniform patient population. The cohort is expected to enroll up to 50 patients, each with two to three prior lines of systemic therapy, and data are anticipated in the third quarter of 2025.

Forward-Looking Statements

Forward-Looking Statements Inhibrx cautions you that statements contained in this Current Report regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx's judgments and beliefs regarding the strength of Inhibrx's pipeline any future potential safety and efficacy of its therapeutic candidate, ozekibart; the clinical development of ozekibart, including expected enrollment in the expansion cohort and data readouts and the timing thereof; the potential demand for ozekibart and any presumption that preliminary data will be representative of final data or data in later clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; results from preclinical studies or early clinical trials not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of its therapeutic candidates that may limit their development, regulatory approval and/or commercialization; the potential for its programs and prospects to be negatively impacted by developments relating to its competitors, including the results of studies or regulatory determinations relating to its competitors; the timing or likelihood of regulatory filings and approvals and regulatory developments in the U.S. and foreign countries; the successful comm

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release issued by Inhibrx Biosciences, Inc. on January 21, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2025 INHIBRX BIOSCIENCES, INC. By: /s/ Kelly Deck Name: Kelly Deck Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR